OpGen Highlights Capabilities of its Acuitas® Technologies to Rapidly Predict Antibiotic Susceptibility Using Drug Resistanc...
April 25 2017 - 8:00AM
OpGen, Inc. (NASDAQ:OPGN) today announced that it has presented
preliminary results supporting its Acuitas Rapid Test in
development to detect antibiotic resistant genes and the use of
predictive algorithms from its Acuitas Lighthouse® Knowledgebase to
predict antibiotic susceptibility. The results were presented at
the 27th European Congress of Clinical Microbiology and Infectious
Diseases (ECCMID) in Vienna, Austria.
The poster, titled “Prediction of antibiotic resistance in
Escherichia coli from resistance genes,” compared phenotypic
antibiotic susceptibility testing (AST) with the emerging
capabilities of Lighthouse Knowledgebase informatics to predict
antibiotic resistance using resistance genes from bacterial
isolates. The results of testing over 1,900 E. coli isolates with
PCR yielded strong prediction of phenotypic antibiotic resistance
for seventeen antibiotics representing seven antibiotic classes
with accuracies ranging from 77% to 97%. Resistance for 12 of the
antibiotics were predicted with 90% or greater accuracy.
A second poster, titled “Rapid outbreak detection of
multidrug-resistant organisms using resistance gene profiles,”
illustrated the potential to detect hospital pathogen outbreaks by
clustering isolates based on resistance gene profiles using a
PCR-based test. Outbreak clusters of P. aeruginosa and E. coli were
accurately discriminated using multiple resistance genes, thereby
demonstrating that a multiplexed PCR-based test has potential to be
a rapid, accurate, and efficient method for surveillance of
multidrug-resistant organisms.
“In the preliminary results presented at ECCMID, our Acuitas
technology demonstrated the ability to rapidly and accurately
predict antibiotic susceptibility using resistance gene profiles,”
said Evan Jones, Chairman and CEO of OpGen. “The development of our
first Acuitas Rapid Test to detect resistance genes for
interpretation by our Acuitas Lighthouse informatics is underway.
The data presented at ECCMID support the potential clinical utility
of this exciting new technology.”
About OpGen OpGen, Inc. is harnessing
the power of informatics and genomic analysis to provide complete
solutions for patient, hospital and network-wide infection
prevention and treatment. Learn more at www.opgen.com and
follow OpGen on Twitter and LinkedIn.
Contact:
OpGen Contact:
Michael Farmer
Director, Marketing
240-813-1284
mfarmer@opgen.com
InvestorRelations@opgen.com
Investor and Media Contact:
MacDougall Biomedical Communications
Cammy Duong
781-591-3443
cduong@macbiocom.com
OpGen (NASDAQ:OPGN)
Historical Stock Chart
From Aug 2024 to Sep 2024
OpGen (NASDAQ:OPGN)
Historical Stock Chart
From Sep 2023 to Sep 2024